{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T00:32:53Z","timestamp":1794875573012,"version":"4.9.1"},"reference-count":30,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Despite a recent increase in therapeutic options, patients with relapsed\/refractory B-cell non-Hodgkin lymphoma (R\/R B-NHL) eventually require novel therapies. We conducted a phase 1 trial of blinatumomab and lenalidomide in R\/R B-NHL. Three dose levels representing 2 schedules were explored. The primary end points were adverse events (AEs) and determining the maximum tolerated dose (MTD)\/recommended phase 2 dose (RP2D). Thirty-five patients were enrolled, and 34 patients initiated treatment with a median number of prior regimens of 3 (range, 2-8). There were no dose-limiting toxicities (DLTs) in the first 2 dose levels. Dose level 3, 20 mg of lenalidomide daily on days 1 to 21 and days 29 to 49 of a 56-day induction cycle plus blinatumomab 9 \u03bcg\/d continuous IV infusion (CIVI) on days 1 to 7, 28 \u03bcg\/d CIVI on days 8 to 14, and 112 \u03bcg\/d CIVI on days 15 to 56 was determined to be the MTD\/RP2D. The most common grade \u22652 AE was neurotoxicity in 11 of 34 patients (32%), with 4 of 16 patients (25%) at the RP2D. At the RP2D, there was 1 DLT, a patient with grade 2 tremor and word-finding difficulty. For all patients completing induction, the overall response rate was 80% (95% confidence interval, 56-94) with a complete response rate of 70%, and 8 of 34 patients (24%) had durable remissions lasting &amp;gt;2 years. GranB+ CD56bright CD16dim CD11b+ natural killer cells and memory regulatory T cells in the peripheral blood at baseline were predictive of response. Concomitant administration of lenalidomide appeared to reduce blinatumomab-mediated T-cell exhaustion. In conclusion, encouraging activity was seen with blinatumomab and lenalidomide in heavily pretreated R\/R B-NHL (NCI Protocol no. 9924).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016845","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T19:55:13Z","timestamp":1762804513000},"page":"1153-1162","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["A phase 1 study of blinatumomab\/lenalidomide in relapsed\/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis"],"prefix":"10.1182","volume":"10","author":[{"given":"Joseph M.","family":"Tuscano","sequence":"first","affiliation":[{"name":"1Division of Malignant Hematology Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA"},{"name":"2Section of Hematology and Oncology, Veterans Administration Northern California Healthcare System, Mather, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Othman","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Frankel","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ruel","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3120-712X","authenticated-orcid":false,"given":"Christina","family":"Poh","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3555-8429","authenticated-orcid":false,"given":"Samantha","family":"Herbert","sequence":"additional","affiliation":[{"name":"1Division of Malignant Hematology Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanual","family":"Maverakis","sequence":"additional","affiliation":[{"name":"1Division of Malignant Hematology Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5735-7233","authenticated-orcid":false,"given":"Alexander A.","family":"Merleev","sequence":"additional","affiliation":[{"name":"1Division of Malignant Hematology Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3338-0583","authenticated-orcid":false,"given":"Guillaume","family":"Luxardi","sequence":"additional","affiliation":[{"name":"1Division of Malignant Hematology Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Abedi","sequence":"additional","affiliation":[{"name":"1Division of Malignant Hematology Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghuveer","family":"Ranganathan","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Oncology University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6525-8844","authenticated-orcid":false,"given":"Dipenkumar","family":"Modi","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, Karmanos Cancer Institute, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4308-629X","authenticated-orcid":false,"given":"Jasmine","family":"Zain","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-5494","authenticated-orcid":false,"given":"Elizabeth L.","family":"Budde","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Mei","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0714-734X","authenticated-orcid":false,"given":"Aaron S.","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"1Division of Malignant Hematology Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus T.","family":"Hoeg","sequence":"additional","affiliation":[{"name":"1Division of Malignant Hematology Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Costello","sequence":"additional","affiliation":[{"name":"7Division of Hematology and Oncology, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7843-3162","authenticated-orcid":false,"given":"Francine M.","family":"Foss","sequence":"additional","affiliation":[{"name":"8Section of Medical Oncology, Yale Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basem M.","family":"William","sequence":"additional","affiliation":[{"name":"9Department of Hematology and Oncology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Kent","family":"Holland","sequence":"additional","affiliation":[{"name":"10Department of Blood and Marrow Transplantation at Northside Hospital, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0044-9719","authenticated-orcid":false,"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[{"name":"11Department of Medicine, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Streicher","sequence":"additional","affiliation":[{"name":"12Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexy","family":"Danilov","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Newman","sequence":"additional","affiliation":[{"name":"12Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"2026022411381820900_bib1","volume-title":"SEER Cancer Statistics Review, 1975-2012","year":"2015"},{"issue":"17","key":"2026022411381820900_bib2","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1158\/1078-0432.CCR-20-4622","article-title":"Long-term follow-up and correlative analysis of two phase II trials of rituximab and lenalidomide followed by continuous lenalidomide in untreated and relapsed\/refractory indolent lymphoma","volume":"27","author":"Tuscano","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026022411381820900_bib3","first-page":"5","article-title":"Epidemiology of non-Hodgkin's lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci (Basel)"},{"issue":"6","key":"2026022411381820900_bib4","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int J Cancer"},{"issue":"11","key":"2026022411381820900_bib5","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"2026022411381820900_bib7","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3389\/fimmu.2020.00762","article-title":"Bispecific, T-cell-recruiting antibodies in B-cell malignancies","volume":"11","author":"Lejeune","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"2026022411381820900_bib8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/hematology.2019000018","article-title":"Mechanisms of and approaches to overcoming resistance to immunotherapy","volume":"2019","author":"Schultz","year":"2019","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"2026022411381820900_bib9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits BSA efficacy through T-cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeir","year":"2021","journal-title":"Blood Can Disc"},{"issue":"3","key":"2026022411381820900_bib10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bjh.12755","article-title":"Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma","volume":"165","author":"Tuscano","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"2026022411381820900_bib11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3109\/10428194.2012.728597","article-title":"Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma","volume":"54","author":"Zhu","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2026022411381820900_bib12","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2013.95","article-title":"Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial","volume":"27","author":"Wang","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"2026022411381820900_bib13","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"14","key":"2026022411381820900_bib14","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"27","key":"2026022411381820900_bib15","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026022411381820900_bib16","doi-asserted-by":"crossref","first-page":"e204787","DOI":"10.1001\/jamanetworkopen.2020.4787","article-title":"Model of a queuing approach for patient accrual in phase 1 oncology studies","volume":"3","author":"Frankel","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"23","key":"2026022411381820900_bib17","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1158\/1078-0432.CCR-19-0438","article-title":"A phase I study of the combination of rituximab and ipilimumab in patients with relapsed\/refractory B-cell lymphoma","volume":"25","author":"Tuscano","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"17","key":"2026022411381820900_bib18","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1158\/1078-0432.CCR-20-4622","article-title":"Rituximab and lenalidomide followed by continuous lenalidomide in untreated and relapsed\/refractory indolent lymphoma: long-term follow-up and correlative analysis","volume":"27","author":"Tuscano","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2026022411381820900_bib19","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"issue":"16","key":"2026022411381820900_bib6","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","article-title":"Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab","volume":"3","author":"Dufner","year":"2019","journal-title":"Blood Adv"},{"issue":"8","key":"2026022411381820900_bib21","doi-asserted-by":"crossref","first-page":"E209","DOI":"10.1002\/ajh.25505","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am J Hematol"},{"issue":"8","key":"2026022411381820900_bib24","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2026022411381820900_bib25","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2021-145694","article-title":"Mosunetuzumab in combination with lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed\/refractory follicular lymphoma: initial results from a phase Ib study","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2026022411381820900_bib26","article-title":"Fixed duration Epcoritamab plus lenalidomide in patients with relapsed or refractory Large B-cell lymphoma(DLBCL) [abstract]","volume":"144","author":"Gurion","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026022411381820900_bib20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nri1549","article-title":"Close encounters of different kinds: dendritic cells and NK cells take centre stage","volume":"5","author":"Degli-Esposti","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2026022411381820900_bib27","doi-asserted-by":"crossref","first-page":"e2836","DOI":"10.1038\/cddis.2017.67","article-title":"Interferon-\u03b3 derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity","volume":"8","author":"Bhat","year":"2017","journal-title":"Cell Death Dis"},{"issue":"8","key":"2026022411381820900_bib28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: from biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"3-4","key":"2026022411381820900_bib29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/10428199709051774","article-title":"Interleukin-10 in non-Hodgkin's lymphoma","volume":"26","author":"Cortes","year":"1997","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"2026022411381820900_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-136279","article-title":"Lenalidomide enhance CAR T-cells response in patients with refractory\/relapsed large B cell lymphoma experiencing progression after infusion","volume":"136","author":"Thieblemont","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2026022411381820900_bib23","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood-2021-151109","article-title":"Lenalidomide exposure at time of CAR T-cells expansion enhances response of refractory\/relapsed aggressive large B-cell lymphomas","volume":"138","author":"Lemoine","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2026022411381820900_bib30","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/ajh.27227","article-title":"Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1153\/2503729\/blooda_adv-2025-016845-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1153\/2503729\/blooda_adv-2025-016845-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:38:25Z","timestamp":1771951105000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/4\/1153\/548128\/A-phase-1-study-of-blinatumomab-lenalidomide-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016845","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,24]]},"published":{"date-parts":[[2026,2,13]]}}}